New vaccine trains immune system to fight ovarian cancer

NCT ID NCT05773859

Recruiting now Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized vaccine made from a patient's own immune cells and tumor material in 10 women with advanced ovarian cancer. The goal is to see if the vaccine can safely boost the immune system to recognize and attack cancer cells after chemotherapy. The study focuses on immune response and safety, not yet on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dendritic cell vaccine made from the patient's own immune cells and tumor material
What this could lead to: If it works, this could point toward a new way to train the immune system to attack ovarian cancer cells, potentially improving long-term control of the disease.
What could go wrong: This is an early phase 1/2 trial with only 10 participants, so results are very preliminary. The vaccine may not produce a strong immune response or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER OVARIAN CARCINOMA

Contacts and locations

Locations

Radboud University Medical Center
RECRUITING

Nijmegen, Gelderland, 6500 HB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.